Progenics Pharmaceuticals (PGNX) Stock Rating Lowered by BidaskClub

Progenics Pharmaceuticals (NASDAQ:PGNX) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other equities research analysts have also recently issued reports on PGNX. ValuEngine cut shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Zacks Investment Research cut shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $15.00 target price on shares of Progenics Pharmaceuticals in a research report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $12.35.

Shares of Progenics Pharmaceuticals (PGNX) opened at $5.41 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.86 and a quick ratio of 7.86. Progenics Pharmaceuticals has a 12-month low of $4.60 and a 12-month high of $11.72. The stock has a market cap of $374.62, a P/E ratio of -6.85 and a beta of 3.40.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. Progenics Pharmaceuticals had a negative net margin of 445.81% and a negative return on equity of 67.61%. The business had revenue of $2.70 million for the quarter, compared to analysts’ expectations of $3.58 million. During the same period last year, the company earned $0.52 earnings per share. The company’s quarterly revenue was down 95.0% on a year-over-year basis. analysts anticipate that Progenics Pharmaceuticals will post -0.92 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of PGNX. Fox Run Management L.L.C. purchased a new position in Progenics Pharmaceuticals in the fourth quarter valued at approximately $100,000. Piedmont Investment Advisors LLC purchased a new position in Progenics Pharmaceuticals in the second quarter valued at approximately $103,000. Aperio Group LLC purchased a new position in Progenics Pharmaceuticals in the third quarter valued at approximately $118,000. Zacks Investment Management purchased a new position in Progenics Pharmaceuticals in the second quarter valued at approximately $145,000. Finally, Municipal Employees Retirement System of Michigan raised its holdings in Progenics Pharmaceuticals by 58.7% in the third quarter. Municipal Employees Retirement System of Michigan now owns 26,350 shares of the biotechnology company’s stock valued at $194,000 after buying an additional 9,750 shares during the period. Hedge funds and other institutional investors own 84.62% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Progenics Pharmaceuticals (PGNX) Stock Rating Lowered by BidaskClub” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/03/progenics-pharmaceuticals-pgnx-stock-rating-lowered-by-bidaskclub.html.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply